The comparative effectiveness and cost-effectiveness of intraocular 90sr brachytherapy/intravitreal vegf inhibitor for neovascular macular degeneration

Evidence-Based Ophthalmology

Volumn 10, Issue 2, 2009, Pages 107-122

  Brown, Gary C ^a   Brown, Melissa M ^a   Brown, Heidi C ^a   Irwin, Blair ^a   Roth, Zachary ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; STRONTIUM 90;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CATARACT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; EPIRETINAL MEMBRANE; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; INVESTMENT; MALE; MEDICAL FEE; OCULAR FIBROSIS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION; UNITED STATES;

EID: 68649106236     PISSN: 15559203     EISSN: 15559211     Source Type: Journal    
DOI: 10.1097/IEB.0b013e31819eadc3     Document Type: Article

References (62)

1. Klein R, Klein BEK, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 2002;109:1767-1779.
2. Friedman DS, O'Colmain BJ, Munoz B, et al, Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122: 564-572.
3. Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration. A value-based analysis. Tr Am Ophthlmol Soc. 2005;103:180-193.
4. Shah AP, Del Priore LV. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Am J Ophthalmol. 2007;143: 83-89.
5. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991; 109:1109-1114.
6. Gragoudas ES, Adamis AP, Cunningham ET, et al, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. New Eng J Med. 2004;351: 2805-2816.
7. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2.Arch Ophthalmol. 2001;119: 198-207.
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an openlabel extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol. 2002; 120:1307-1314.
9. Brown GC, Brown MM, Roth Z, et al. The costutility of photodynamic therapy in eyes with neovascular age-related macular degeneration. A reappraisal with 5-year data. Am J Ophthalmol. 2005;140:679-687.
10. Rosenfeld PJ, Brown DM, Heier JS, et al, for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med. 2006;355:1419-1431.
11. Boyer DS, Antoszyk AN, Awh CC, et al, for the MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246-252.
12. Brown GC, Brown MM, BrownH,et al. Avaluebased medicine analysis of ranibizumab (MARINA Study) for the treatment of subfoveal neovascular macular degeneration. Ophthalmology. 2008;115:1039-1045.
13. Bashshur ZF, Haddad ZA, Schakal RF, et al. Intravitreal bevacizumab for treatment of agerelated macular degeneration: A one-year prospective study. Am J Ophthalmol. 2008;145: 249-256.
14. Marcus DM, Peskin E, Maguire M, et al, AMDRT Research Group. The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol. 2004;138:818-828.
15. Jaakkola A, Heikkonen J, Tommila P, et al. Strontium plaque irradiation of subfoveal neovascular membranes in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 1998;236:24-30.
16. Jaakkola A, Heikkonen J, Tommila P, et al. Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology. 2005;112:567-573.
17. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-223.
18. Brown MM, Brown GC, Sharma S. EvidenceBased to Value-Based Medicine. Chicago: AMA Press; 2005:151-265.
19. Avila MP, Farah ME, Santos A, et al. Twelvemonth safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina. 2009;29:157-169.
20. Arias E. United States Life Tables. National Vital Statistics Reports. Vol 3, No. 6. Hyattsville, Maryland: National Center for Health Statistics; 2004.
21. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85: 327-331.
22. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc. 1999;97:473-512.
23. Brown GC, Brown MM, Sharma S, et al. Utility values associated with age-related macular degeneration. Arch Ophthalmol. 2000;118:47-51.
24. Brown MM, Brown GC, SharmaS,etal. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481-484.
25. Brown MM, Brown GC, Sharma S, et al. Utility values and diabetic retinopathy. Am J Ophthalmol. 1999;128:324-330.
26. SharmaS,Brown GC, Brown MM, etal. Validity of the time trade-off and standard gamble methods of utility assessment in retinal patients. Br J Ophthalmol. 2002;86:493-496.
27. Brown GC, Brown MM, Sharma S, et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc. 2001;99:71-76.
28. Brown GC, Brown MM, Sharma S. Difference between ophthalmologist and patient perceptions of quality-of-life associated with age-related macular degeneration. Can J Ophthalmol. 2000;35:27-32.
29. Stein JD, Brown MM, Brown GC, et al. Quality of life with macular degeneration. Perceptions of patients, clinicians and community members. Brit J Ophthalmol. 2003;87:8-12.
30. Brown GC, Brown MM. Quality-of-Life Utility Database. Flourtown, PA: Center for Value-Based Medicine; 2007:1-519.
31. Brown GC, Shields JA, Sanborn G, et al. Radiation retinopathy. Ophthalmology. 1982;89: 1494-150l.
32. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276: 1339-1341.
33. Brown GC, Brown MM, SharmaS. Incremental cost-effectiveness of laser therapy for subfoveal choroidal neovascularization. Ophthalmology. 2000;107:1374-1380.
34. Busbee B, Brown MM, Brown GC, et al. A costutility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina. 2003;23:279-287.
35. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of therapeutic interventions for branch retinal vein occlusion. Ophthal Epidemiol. 2002;9:1-10.
36. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2001;108: 2051-2059.
37. Brown GC, Brown MM, Sharma S, et al. A costutility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol. 2002;133: 365-372..
38. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol. 1997;115:741-747.
39. Drummond ME, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford University Press; 1999.
40. Heudebert GR, Centor RM, Klapow JC, et al. What is heartburn worth?A cost-utility analysis of management strategies. J Gen Intern Med. 2000;15:175-182.
41. Kallmes DF, Kallmes MH. Cost-effectiveness of angiography performed during surgery for rup- tured intracranial aneurysms. AJNR Am J Neuroradiol. 1997;18:1453-1462.
42. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization: tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146: 473-481.
43. The World Health Organization. The World Health Report 2002-Reducing Risks, Promoting Healthy Life, pp 47-96. From the Internet @ http://www.who.int/whr/2002/en/index.html, accessed March 18, 2008.
44. National Institute for Health and Clinical Excellence (NICE). Incorporating health economics in guidelines and assessing resource impact. The Guidelines Manual, London, NICE, 2007, Chap 8. Available on the Internet @ http://www.nice.org.uk/page.aspx?o=422950, accessed 3-15-08.
45. Schmier JK, Halpern MT, CovertD,etal. Impact of visual impairment on use of caregiving by individuals with age-related macular degeneration. Retina. 2006;26:1056-1062.
46. Bureau of Labor and Statistics. Data on disability and unemployment. 1991/92, 1993/94, 1994/95, and 1997. From the Survey of Income and Program Participation. From the Internet @ www.bls.census.gov, accessed April 4, 2008.
47. National Alliance on Mental Illness. Social Security and disability benefits. From the Internet @ http://64.233.169.104/search?q=cache: AyOPnzBg4SsJ:www.nami.org/ Content/ContentGroups/Helpline1/Social-Security-and- Dis-ability-Benefits.htm +social + security +disability + average+payment& hl= en&ct= clnk &cd=5&gl=us&ie= UTF-8, accessed 4-6-08.
48. Suddenly Senior. From the Internet @ http://www. suddenlysenior.com/ advertisess.html, accessed 4-6-08.
49. Political calculations. Average wages in the US. http:// politicalcalculations.blogspot.com/2008/ 01/remodeling-average-wage-in-us.html, accessed 4-6-08.
50. Rosenfeld PJ. Real-world dosing strategies for ranibizumab. Retina Today. 2007;3:11-13.
51. Brown GC, Brown MM, Brown H,et al.Avaluebased medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology. 2007;114:1170-1178.
52. Busbee B, Brown MM, Brown GC, et al. A costutility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310-2317.
53. Busbee B, Brown MM, Brown GC, et al. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109:606-612.
54. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics. 1999; 104:e47.
55. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol. 1997;92:2179-2187.
56. Mushlin AI, Mooney C, Holloway RC, et al. The cost-effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms. Int J Tech Assess Health Care. 1997; 13:21-34.
57. Hayman JA, Hillner BE, Harris JR, et al. Costeffectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol. 1998;16:1022-1029.
58. Joshi AV, Munro V, Russell MW. Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006;22:351-357.
59. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 1997;157:1972-1980.
60. Smith KG, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics. 2000;18: 95-104..
61. Touchette DR, Durgin TL, Wanke LA, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003;25:611-634.
62. Touchette DR, Durgin TL, Wanke LA, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther. 2003;25:611-634.